| pubmed-article:8915713 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C0530993 | lld:lifeskim |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C0681916 | lld:lifeskim |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C0750572 | lld:lifeskim |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C0680844 | lld:lifeskim |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C1522609 | lld:lifeskim |
| pubmed-article:8915713 | lifeskim:mentions | umls-concept:C1554112 | lld:lifeskim |
| pubmed-article:8915713 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8915713 | pubmed:dateCreated | 1997-2-26 | lld:pubmed |
| pubmed-article:8915713 | pubmed:abstractText | Cytokeratin-19, one of the cytoskeletal proteins, is expressed both in bronchial epithelium and in lung cancer cells. The aim of our study was to establish the value of serum cytokeratin-19 soluble fragment (Cyfra 21-1) measurement in lung cancer patients. Cyfra 21-1 levels were estimated in 35 patients (pts) with benign lung diseases and in 116 lung cancer patients: 55 pts with squamous cell lung cancer, 38 pts with small cell lung cancer and 23 pts with adenocarcinoma. The cutoff level was set at 4 ng/ml with a specificity of 94% and a sensitivity of 40%. Elevated Cyfra 21-1 values were found in 44% of squamous cell lung cancer, 39% of adenocarcinoma and 34% of small cell lung cancer pts (the difference was not significant). In squamous cell lung cancer and in adenocarcinoma elevated Cyfra 21-1 values were observed more often in patients with advanced disease than in patients with limited disease. There was no significant correlation between the initial Cyfra 21-1 level and the response to chemotherapy. Cyfra 21-1 was not a prognostic indicator, although in operable squamous cell lung cancer the proportion of survivors in the second year of observation was higher among the patients with normal preoperative Cyfra 21-1 levels. | lld:pubmed |
| pubmed-article:8915713 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8915713 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8915713 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8915713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8915713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8915713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8915713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8915713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8915713 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8915713 | pubmed:issn | 0393-6155 | lld:pubmed |
| pubmed-article:8915713 | pubmed:author | pubmed-author:ZaleskaJJ | lld:pubmed |
| pubmed-article:8915713 | pubmed:author | pubmed-author:RudzinskaHH | lld:pubmed |
| pubmed-article:8915713 | pubmed:author | pubmed-author:ZychJJ | lld:pubmed |
| pubmed-article:8915713 | pubmed:author | pubmed-author:WiatrEE | lld:pubmed |
| pubmed-article:8915713 | pubmed:author | pubmed-author:SakowiczAA | lld:pubmed |
| pubmed-article:8915713 | pubmed:author | pubmed-author:SzturmowiczMM | lld:pubmed |
| pubmed-article:8915713 | pubmed:author | pubmed-author:Rowinska-Zakr... | lld:pubmed |
| pubmed-article:8915713 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8915713 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:8915713 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8915713 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8915713 | pubmed:pagination | 172-7 | lld:pubmed |
| pubmed-article:8915713 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:meshHeading | pubmed-meshheading:8915713-... | lld:pubmed |
| pubmed-article:8915713 | pubmed:articleTitle | The clinical value of Cyfra 21-1 estimation for lung cancer patients. | lld:pubmed |
| pubmed-article:8915713 | pubmed:affiliation | Dept. of Internal Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland. | lld:pubmed |
| pubmed-article:8915713 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8915713 | lld:pubmed |
